About Us
Faculty
Conditions & Procedures
Patient Stories
Patient Center
Clinic Information
- Request an Appointment
- Refer a Patient
- Locations & Directions
Clinical Trials at UCSF
- Clinical Trials
Resources
- Ostomy Education
- Enhanced Recovery After Surgery (ERAS)
Ostomy Education
- Ostomy Education Patient Portal
Research
Clinical Research
- Outcomes & QOL Studies
Clinical Coordinators
- Adriana Chou
News & Events
Emily Bergsland, M.D.
- Professor of Clinical Medicine
- Division of Hematology Oncology
- Department of Medicine
- Ernest Rosenbaum, MD Endowed Chair of Medical Oncology
Education
UniversUniversity of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982
Residencies
- 1989-92, Intern, Dept. of Medicine, University of California San Francisco
- 1990-92, Resident, Dept. of Medicine, University of California San Francisco
- 1992-92, Chief Resident and Assistant Chief of the Medical Service, Dept. of Medicine, University of California San Francisco
Postdoctoral Training
- 1994-1992, Research Fellow (P I: Douglas Hanahan, Ph.D.), Department of Biochemistry and Biophysics, University of California San Francisco
Clinical Expertise
- Colon Cancer
- Esophageal Cancer
- Liver Cancer
- Lynch Syndrome
- Pancreatic Cancer
- Rectal Cancer
- Stomach Cancer
Biography
Dr. Emily Bergsland is currently a Professor of Clinical Medicine and holds the Ernest Rosenbaum, MD Endowed Chair of Medical Oncology. She received her medical degree from the University of Minnesota and completed an internship, residency, and chief residency in internal medicine at UCSF. She subsequently completed a fellowship in Medical Oncology and was a Molecular Medicine fellow before joining the UCSF faculty in 1998.
Dr. Bergsland has led numerous clinical studies in patients with gastrointestinal malignancies. Her current efforts are focused on clinical and translational research related to neuroendocrine tumors. At a national level, Dr. Bergsland is a member of the Neuroendocrine Tumor Task force for the National Cancer Institute and a member of the NCCN NET guidelines panel. She is also the study chair for a national study of a novel treatment for patients with carcinoid tumors performed by the ALLIANCE for Clinical Trials and funded by the National Cancer Institute.
Cancer surgeon Eric Nakakura, M.D., Ph.D. and medical oncologist Emily Bergsland, M.D. discussing carcinoid syndrome
Research & Funding
Data provided by UCSF Profiles, powered by CTSI
- UCSF Paul Calabresi K12 Career Development Program in Clinical OncologySponsor: NIHSponsor ID: K12CA260225Funding Period:Jul 2021-Jun 2026Principal Investigator
Clinical Trials
Data provided by UCSF Profiles, powered by CTSI
- Study ID: NCT05746208Start Date: Apr 2023Estimated Completion Date: Jul 2027Condition(s): Neuroendocrine Tumor, Neuroendocrine Carcinoma, Carcinoma
- Study ID: NCT05746182Start Date: Apr 2023Estimated Completion Date: Dec 2025Condition(s): Pancreatic Neuroendocrine Neoplasm, Neoplasms, Neuroendocrine Tumor
- Study ID: NCT04665739Start Date: Sep 2021Estimated Completion Date: Jul 2024Condition(s): Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Neuroendocrine Tumor
- Study ID: NCT03375320Start Date: Jul 2018Estimated Completion Date: Jan 2022Condition(s): Carcinoid Tumor, Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Metastatic Thymic Neuroendocrine Neoplasm, Neuroendocrine Neoplasm
- Study ID: NCT03136055Start Date: Jun 2017Estimated Completion Date: Jun 2020Condition(s): Malignant Neuroendocrine Carcinoma (Diagnosis)
- Study ID: NCT01841736Start Date: Jun 2013Estimated Completion Date: Jan 0001Condition(s): Carcinoid Tumor, Neuroendocrine Tumor
- Study ID: NCT01824875Start Date: Apr 2013Estimated Completion Date: Jul 2023Condition(s): Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Pancreatic Tumor, Somatostatinoma
- Study ID: NCT00843531Start Date: Jun 2009Estimated Completion Date: Aug 2016Condition(s): Neuroendocrine Tumor
- Study ID: NCT00390156Start Date: Aug 2006Estimated Completion Date: Jan 2011Condition(s): Solid Tumor
- Study ID: NCT00227617Start Date: Jun 2005Estimated Completion Date: Feb 2016Condition(s): Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 140
Data provided by UCSF Profiles, powered by CTSI
- Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. Br J Cancer. 2023 May 19. View in PubMed
- Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovittz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Consensus recommendations for management of high grade neuroendocrine tumors. Endocr Relat Cancer. 2023 May 01. View in PubMed
- Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. J Neuroendocrinol. 2023 Apr; 35(4):e13260. View in PubMed
- Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review. Clin Genitourin Cancer. 2023 Mar 17. View in PubMed
- Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis. Eur J Cancer. 2023 Mar; 182:43-52. View in PubMed
- View All Publications
In the News
- UCSF Surgical Oncology Program - - January 03, 2017Eric Nakakura, M.D., Ph.D., a UCSF gastrointestinal cancer surgeon and Emily Bergsland, M.D.. a UCSF gastrointestinal oncologist, recently discussed the treatment of carcinoid syndrome on "Healthy Body, Healthy Mind", a series hosted by Information Television Network (ITV), a PBS content affiliate. Dr. Nakakura is an Associate Professor in the UCSF Department of Surgery and Dr. Bergsland a Professor in the UCSF Department of Medicine. The ITV episode, which portrays the struggles of Ray Martz [...]